BioSpace News Archive

Creative sketch collage of business people handshake gesture approval project development success colleagues cooperation support.

Manufacturing

Big Pharma Tight-Lipped on Details of API Stockpile Deals

Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are keeping many of the terms of their agreements private.

January 27, 2026

·

4 min read

·

Nick Paul Taylor

Illustration of woman checking progress on project

Opinion

FDA Inspections Should Not Be Source of Stress

True inspection readiness is about the integrity of a company’s entire system.

January 27, 2026

·

5 min read

·

Greg Walker

The Westin St. Francis in San Francisco, home of the J.P. Morgan Healthcare Conference.

JPM

JPM26: Biopharma Projected Positivity in San Francisco. Now It’s Time To Execute

With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.

January 27, 2026

·

6 min read

·

Annalee Armstrong

Businessman holding briefcase walking on graphic stair, start up business concepts.

GLP-1

Roche’s 22% Weight Loss Benefit Seals GLP-1’s Phase III Plans, Boosts Zealand Combo

Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.

January 27, 2026

·

2 min read

·

Annalee Armstrong

Composite contemporary collage statue of justice themis femida on the background of the target as the concept and idea of justice and law. High quality photo

Legal

CytoDyn’s Former CEO Gets Jail Time, $5.3M+ Fine for Securities Fraud

Nader Pourhassan, who led CytoDyn for nearly 10 years, was convicted in December 2024 of misleading investors regarding the biotech’s investigational COVID-19 and HIV drug, which artificially inflated its share price.

January 27, 2026

·

2 min read

·

Tristan Manalac

The headquarters of Intellia Therapeutics, a brick building with two triangular shapes in its roof

Gene editing

FDA Lifts One of Two Clinical Holds on Intellia’s ATTR Gene Editing Program

After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs for hereditary transthyretin amyloidosis.

January 27, 2026

·

2 min read

·

Dan Samorodnitsky

The man opens the door. The concept of mystery or new opportunities or the path to the future.

GLP-1

Baseline Debuts To Challenge GLP-1 Giant Lilly in Alcohol Use Disorder

While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP-1 asset BT-001 into late-stage development, with two trials planned this year.

January 27, 2026

·

2 min read

·

Tristan Manalac

Pictured: Boehringer Ingelheim's office in California

Inflammatory bowel disease

Boehringer Commits up to $1.26B in IBD Pact With China’s Simcere

The cornerstone of the deal is SIM0709, which Simcere designed to target both TL1A and IL-23, crucial players in facilitating inflammation. Boehringer Ingelheim will advance the asset for inflammatory bowel diseases.

January 27, 2026

·

2 min read

·

Tristan Manalac

Press Releases

Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma

January 27, 2026

·

7 min read

Press Releases

QIAGEN Appoints Mark Stevenson to Supervisory Board

January 27, 2026

·

6 min read